A carregar...
Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3165303/ https://ncbi.nlm.nih.gov/pubmed/21709084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00104-11 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|